Coultreon Biopharma raises $125M in Series A funding led by Sofinnova Investments, Forbion, and Novo Holdings to advance its lead immunology program.
Amount Raised
$125 Million
Round Type
Series A
Investors
Description
Coultreon Biopharma, a Leuven-based biotechnology company, raised $125M in Series A funding. The investment was led by Sofinnova Investments, Forbion, and Novo Holdings with several other participants. The company plans to use the funds to support the clinical development of its lead program, COL-5671. This highly selective SIK3 inhibitor is currently in Phase 1 studies for autoimmune diseases.
Quick answer
Coultreon Biopharma raised $125 Million in a Series A round, dated April 28, 2026. Investors: Balyasny Asset Management, Galapagos, Samsara Biocapital, Novo Holdings, Longwood Fund, Luma Group, Regeneron Ventures and Finchley Healthcare Ventures.
- How much did Coultreon Biopharma raise?
- Coultreon Biopharma raised $125 Million in a Series A round on April 28, 2026.
- Who invested in Coultreon Biopharma?
- Balyasny Asset Management, Galapagos, Samsara Biocapital, Novo Holdings, Longwood Fund, Luma Group, Regeneron Ventures and Finchley Healthcare Ventures are named as investors in this round.
- What does Coultreon Biopharma do?
- Coultreon Biopharma, formerly known as Onco3R Therapeutics, is a biotechnology company based in Leuven, Belgium.
- Where is Coultreon Biopharma based and how big is it?
- Fundz records about 22 employees.
- Who are the decision-makers at Coultreon Biopharma?
- Fundz holds 2 contacts at Coultreon Biopharma, including the Chief Technology & Operations Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Coultreon Biopharma that raised within 45 days of this round, from Fundz verified event records.
- Beren Therapeutics raised $300M (Debt Financing) on June 10, 2026.
- Circio Holding ASA raised $34M (Post-IPO Equity) on June 10, 2026.
- City Therapeutics raised $100M (Series B) on June 8, 2026.
- Goldenrod Therapeutics raised $6.5M (Seed) on June 4, 2026.
- Ona raised $87M (Series B) on June 4, 2026.
- Tolerance Bio raised $15M on June 3, 2026.
Who to call at Coultreon Biopharma, and when
A new round usually means Coultreon Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Coultreon Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Coultreon Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Coultreon Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Coultreon Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCoultreon Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.